autologous vaccine-enhanced ex vivo activated cancer neoantigens-specific T cells TVI-Brain-1

A preparation of autologous T lymphocytes collected from the patient after the administration of a personalized cancer vaccine composed of an attenuated form of patient-specific cancer cells and an immunological adjuvant, via leukapheresis, and activated ex vivo, with potential immunostimulating and antineoplastic activities. Cancer neoantigens-specific T cells are collected after the administration of the personalized cancer vaccine and expanded ex vivo. Upon administration, the autologous vaccine-enhanced ex vivo activated cancer neoantigens-specific T cells TVI-Brain-1 recognize and bind to tumor cells expressing the cancer neoantigens, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells.